Search for: "U.S. Pharmaceutical Corporation" Results 1 - 20 of 1,594
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
31 May 2024, 10:44 am by Dennis Crouch
Rob Honeycutt, an individual inventor, states that “ongoing continuations with terminal disclaimers are one of the few remaining advantages available to defend intellectual property rights against infinitely larger corporate entities. [read post]
9 May 2024, 9:01 am by Seeger Weiss
With the resources and dedication to take on the world’s largest corporations, the firm has an impressive track record of victories against companies like Merck, Monsanto, and 3M—and a reputation for sticking with a case from beginning to end. [read post]
1 May 2024, 1:18 pm by Melissa Tremblay
Teva Pharmaceuticals, an AKS-based FCA case involving speaker programs sponsored by drug manufacturers, the U.S. [read post]
9 Apr 2024, 2:56 pm by Brian Clark
A non-exclusive list including some of the more important IP related capitalized costs (and certain exceptions) in commercial and corporate transactions today follows: Creation Costs. [read post]
3 Apr 2024, 1:28 pm by Kevin LaCroix
Readers know that since the initial coronavirus-related outbreak in the U.S. in March 2020, I have been tracking the COVID-related securities suit filings. [read post]
20 Mar 2024, 12:37 pm by Dr. Shezad Malik
“This case is a blatant example of environmental pollution and corporate malfeasance that directly caused immense physical harm to our client. [read post]
18 Mar 2024, 6:27 am by Second Circuit Civil Rights Blog
Pfizer, the pharmaceutical company, has a fellowship program that seeks to advance students and "early career colleagues of Black/American, Latino/Hispanic and Native American descent. [read post]
5 Mar 2024, 2:25 pm by Harbir Deol
The BOPREAL bonds are subscribed in pesos at the official exchange rate, denominated in U.S. dollars, and payable in U.S. dollars. [read post]
12 Feb 2024, 6:07 am by Kevin LaCroix
  Plan sponsors have no incentive to overpay for health plan services because it is a material corporate expense. [read post]
24 Jan 2024, 9:01 pm by renholding
Would a pharmaceutical company that takes more than 12 or 18 months to bring a drug to market suddenly find itself primarily engaged in the business of investing in securities? [read post]